Ginkgo Bioworks (DNA) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings or view top-rated stocks.

5 brokers have issued 12 month target prices for Ginkgo Bioworks' stock. Their DNA share price forecasts range from $1.25 to $6.00. On average, they anticipate the company's stock price to reach $3.75 in the next year. This suggests a possible upside of 111.9% from the stock's current price.
View analysts price targets for DNA or view top-rated stocks among Wall Street analysts.

Ginkgo Bioworks' stock was trading at $1.69 at the beginning of the year. Since then, DNA stock has increased by 4.7% and is now trading at $1.77.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our DNA earnings forecast.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.09). The company earned $80.57 million during the quarter, compared to analysts' expectations of $70.41 million. Ginkgo Bioworks had a negative trailing twelve-month return on equity of 66.58% and a negative net margin of 375.48%.

ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include VegTech Plant-based Innovation & Climate ETF (EATV), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Direxion Moonshot Innovators ETF (MOON), WisdomTree BioRevolution Fund (WDNA), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Range Cancer Therapeutics ETF (CNCR).

Ginkgo Bioworks issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $245.00 million-$260.00 million, compared to the consensus revenue estimate of $292.83 million.

Ginkgo Bioworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "DNA."

Ginkgo Bioworks' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (11.56%), ARK Investment Management LLC (8.14%), BlackRock Inc. (3.27%), Sumitomo Mitsui Trust Holdings Inc. (2.44%), State Street Corp (0.99%) and Geode Capital Management LLC (0.83%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends.

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNA stock can currently be purchased for approximately $1.77.

Ginkgo Bioworks (NYSE:DNA) has a market capitalization of $3.71 billion and generates $477.71 million in revenue each year. The company earns $-2,104,930,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

The company employs 1,292 workers across the globe.

Ginkgo Bioworks' mailing address is 955 Fifth Avenue, New York NY, 10075. The official website for the company is www.eagleequityptnrs.com. The company can be reached via phone at 877-442-5362 or via email at investors@ginkgobioworks.com.